Therefore, it is necessary to investigate the therapeutic potential of ISA-2011B on inhibiting the PI3K/AKT pathway in breast cancer as a targeted and possibly more effective therapy for patients with activated PI3K/AKT [17–21]. This evidence concerns the gene PIK3CA and breast cancer.